XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Other Events
Item 8.01
|
Other Events |
On March 24, 2017, Xenon Pharmaceuticals Inc. (the Company)
issued a press release announcing results from the double-blind,
multi-center, vehicle-controlled, parallel-group study designed
to evaluate the efficacy, safety, tolerability and systemic
exposure of XEN801 for the treatment of moderate to severe facial
acne.A copy of the Companys press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release issued by Xenon Pharmaceuticals Inc. dated |
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801. XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Recent Trading Information
XENON PHARMACEUTICALS INC. (NASDAQ:XENE) closed its last trading session down -5.20 at 4.65 with 321,845 shares trading hands.
